Aduhelm’s costs: Medicare recipients won’t get premium reduction until 2023
By
Alicia Lasek (f3)
Jun 01, 2022
A cost overestimate that bumped up Medicare premiums for seniors in 2022 will not be corrected until the following year. The spike is tied to coverage for Alzheimer’s drug Aduhelm.
House committees to investigate new Alzheimer’s disease drug approval
Jul 01, 2021
FDA approved Aduhelm earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness
